<DOC>
	<DOCNO>NCT01104532</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , pharmacodynamics safety follow administration ASP1941 sitagliptin single multiple dos .</brief_summary>
	<brief_title>A Study Characterize Effect Pharmacokinetics ASP1941 Sitagliptin When Given Together Healthy Subjects</brief_title>
	<detailed_description>All subject enrol one center confine unit 17 day . Subjects dose fast state one four group .</detailed_description>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>The subject weigh least 50 kg , body mass index ( BMI ) 18 32 kg/m2 inclusive The subject 's 12lead electrocardiogram ( ECG ) result normal The female subject must least two year postmenopausal , surgically sterile practice effective birth control pregnant lactate The male female subject agree practice highly effective birth control Screening 7 day post last dose The subject history evidence clinically significant cardiovascular , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy ( exclude nonmelanoma skin cancer ) The subject evidence renal insufficiency ( serum creatinine ≥ 1.5 men ≥ 1.3 woman ) The subject history cholelithiasis acute pancreatitis The subject condition possibly affect drug absorption ( e.g. , gastrectomy ) The subject history consume 14 unit alcoholic beverage per week within last 6 month history alcoholism drug/chemical/substance abuse within past 2 year subject test positive alcohol drug abuse The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic checkin The subject supine mean systolic blood pressure &lt; 90 &gt; 160 mm/Hg mean diastolic blood pressure &lt; 50 &gt; 90 , pulse rate high 100 beat per min ( bpm ) The subject 12lead ECG demonstrate QTcF &gt; 470 msec ( female ) &gt; 450 msec ( male ) The subject know positive human immunodeficiency virus ( HIV ) antibody The subject positive test tuberculosis ( TB ) , hepatitis C antibody , positive hepatitis B surface antigen ( HGsAg ) The subject use prescription nonprescription drug within 14 day 5 halflives ( whichever longer ) complementary alternative medicine ( CAM ) within 14 day prior study drug administration ( exclude oral contraceptive , hormone replacement therapy [ HRT ] , acetaminophen ) The subject vaccinate within last 7 day The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Januvia</keyword>
	<keyword>sitagliptin</keyword>
</DOC>